SABCS 2019

ESMO 2019

Molecular Cancer Therapeutics

Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors.

A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment.

Serial changes in tumor-derived whole-genome cfDNA fraction to identify early disease progression prior to imaging.

Detection of Somatic Copy Number Aberrations in cfDNAfrom Patients with Solid Tumor Malignancies.

Comparison of bisulfite- and methyl-capture approaches for mapping the cell-free methylome in late-stage cancer patients.

Client Services: (888) 988-3639

Biopharma Solutions:


150 Second Street, Cambridge, MA 02141  •  (617) 418-2200